Literature DB >> 25284697

Optimal medication dosing in patients with diabetes mellitus and chronic kidney disease.

Lori MacCallum1.   

Abstract

Diabetes mellitus is the leading cause of chronic kidney disease (CKD) in Canada. As rates of diabetes rise, so does the prevalence of CKD. Diabetes and CKD are chronic diseases that require multiple medications for their management. Many of the anticipated effects of these medications are altered by the physiologic changes that occur in CKD. Failure to individualize drug dosing in this population may lead to toxicity or decreased therapeutic response, leading to treatment failure. At times this can be challenging for a multitude of reasons, including the limitations of available calculations for estimating renal function, inconsistent dosing recommendations and the lack of dosing recommendations for some medications. Clinicians caring for these patients need to consider an approach of individualized drug therapy that will ensure optimal outcomes. The better understanding that clinicians have of these challenges, the more effective they will be at using the available information as a guide together with their own professional judgement to make appropriate dosing changes. This article discusses the following: 1) physiologic changes that occur in CKD and its impact on drug dosing; 2) advantages and disadvantages of various calculations used for estimating renal function; 3) pharmacokinetic and pharmacodynamic changes of some commonly used medications in diabetes, and finally, 4) an approach to individualized drug dosing for this patient population.
Copyright © 2014 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  atteinte rénale; chronic kidney disease; diabetes; diabète; medication dosing; néphropathie chronique; posologie; renal impairment

Mesh:

Substances:

Year:  2014        PMID: 25284697     DOI: 10.1016/j.jcjd.2014.04.006

Source DB:  PubMed          Journal:  Can J Diabetes        ISSN: 1499-2671            Impact factor:   4.190


  5 in total

1.  Individualizing drug therapy in patients with diabetes and chronic kidney disease.

Authors:  Lori MacCallum
Journal:  Can Pharm J (Ott)       Date:  2015-09

2.  Development and Application of the GheOP3S-Tool Addendum on Potentially Inappropriate Prescribing (PIP) of Renally Excreted Active Drugs (READs) in Older Adults with Polypharmacy.

Authors:  Abdul Aziz Al Wazzan; Eline Tommelein; Katrien Foubert; Stefano Bonassi; Graziano Onder; Annemie Somers; Mirko Petrovic; Koen Boussery
Journal:  Drugs Aging       Date:  2018-04       Impact factor: 3.923

Review 3.  Management of glycemia in diabetic patients with stage IV and V chronic kidney disease.

Authors:  Andrea Roche-Recinos; Esti Charlap; Mariana Markell
Journal:  Curr Diab Rep       Date:  2015-05       Impact factor: 4.810

4.  Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment.

Authors:  Markolf Hanefeld; Juan M Arteaga; Lawrence A Leiter; Giulio Marchesini; Elena Nikonova; Marina Shestakova; William Stager; Ricardo Gómez-Huelgas
Journal:  Diabetes Obes Metab       Date:  2017-06-07       Impact factor: 6.577

5.  Therapeutic Silencing of Centromere Protein X Ameliorates Hyperglycemia in Zebrafish and Mouse Models of Type 2 Diabetes Mellitus.

Authors:  Liqing Zang; Yasuhito Shimada; Hiroko Nakayama; Wenbiao Chen; Ayaka Okamoto; Hiroyuki Koide; Naoto Oku; Takehisa Dewa; Masayuki Shiota; Norihiro Nishimura
Journal:  Front Genet       Date:  2019-07-29       Impact factor: 4.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.